undamentalytics Newsletter
Sign in

Jazz Pharmaceuticals plc income statement

In fiscal 2025, Jazz Pharmaceuticals plc reported revenue of $4.27bn, up 4.9% on the year before, operating income of −$430m (a -10.1% margin) and net income of −$356m, or −$5.84 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue1281742725868721,1731,3251,4881,6191,8912,1622,3643,0943,6593,8344,0694,2684,718
Research and development372614204285135162198227300335506590850884783829
Selling, general and administrative59691092243044064495035446847378541,4521,4171,3431,3851,8091,556
Operating income1658128198340196508592529615532378170−66579717−430426
Interest expense23132———272838576388903333———
Income before tax—33125177308152436532441529454275−113−373298470−628260
Income tax—00−849294106135−4880−7334216−159−120−91−27254
Net income−73312528921658330397488447523239−330−224415560−356206
Diluted EPS−$0.23$0.83$2.67$4.79$3.51$0.93$5.23$6.41$7.96$7.30$9.09$4.22−$5.52−$3.58$6.10$8.65−$5.84$3.16
Diluted shares (average)30m39m47m60m62m63m63m62m61m61m58m57m60m63m72m66m61m65m
EBITDA1759128199343203518603542630548397197−35609749−389461

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ELAN vs JAZZJAZZ vs OGNAMRX vs JAZZ

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Jazz Pharmaceuticals plc's SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Jazz Pharmaceuticals plc.